QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Vol. 17, Issue 4, 1995-2008, April 2006

This Article Abstract Full Text (PDF) All Versions of this Article: E05-09-0869v1 17/4/1995    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Short, M. D. Articles by Das, M. Search for Related Content PubMed PubMed Citation Articles by Short, M. D. Articles by Das, M.

Protein Kinase C Attenuates Hypoxia-induced Proliferation of Fibroblasts by Regulating MAP Kinase Phosphatase-1 Expression

Developmental Lung Biology Research Laboratory, Department of Pediatrics, University of Colorado Health Sciences Center, Denver, CO 80262

Submitted September 20, 2005; Revised January 5, 2006; Accepted January 31, 2006
Monitoring Editor: Richard Assoian

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGMENTS REFERENCES

 
We have previously found that hypoxia stimulates proliferation of vascular fibroblasts through Gi-mediated activation of ERK1/2. Here, we demonstrate that hypoxia also activates the atypical protein kinase C (PKC) isozyme and stimulates the expression of ERK1/2-specific phosphatase, MAP kinase phosphatase-1 (MKP-1), which attenuates ERK1/2-mediated proliferative signals. Replication repressor activity is unique to PKC because the blockade of classical and novel PKC isozymes does not affect fibroblast proliferation. PKC is phosphorylated upon prolonged (24 h) exposure to hypoxia, whereas ERK1/2, the downstream kinases, are maximally activated in fibroblasts exposed to acute (10 min) hypoxia. However, PKC blockade results in persistent ERK1/2 phosphorylation and marked increase in hypoxia-induced replication. Similarly prolonged ERK1/2 phosphorylation and increase in hypoxia-stimulated proliferation are also observed upon blockade of MKP-1 activation. Because of the parallel suppressive actions of PKC and MKP-1 on ERK1/2 phosphorylation and proliferation, the role of PKC in the regulation of MKP-1 expression was evaluated. PKC attenuation reduces MKP-1 expression, whereas PKC overexpression increases MKP-1 levels. In conclusion, our results indicate for the first time that hypoxia activates PKC, which acts as a terminator of ERK1/2 activation through the regulation of downstream target, MKP-1 expression and thus serves to limit hypoxia-induced proliferation of fibroblasts.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGMENTS REFERENCES

 
Fibroblast proliferation is associated with various forms of vascular diseases (Sartore et al., 2001), different fibrotic conditions (Atamas, 2002) and cancer (Bhowmick et al., 2004). Hypoxia is the critical contributor to the pathophysiological conditions of these diseases. We have found that cultured vascular adventitial fibroblasts have the distinct capability to proliferate directly in response to hypoxia in the absence of any exogenous growth factors (Das et al., 2001). Intracellular signaling intermediates, e.g., protein kinase C (PKC) and MAP kinase families are the major mediators of hypoxic signal stimulating replication of cells (Das et al., 2000, 2001; Sodhi et al., 2000). However, cellular proliferation is tightly regulated by proper exit from the cell cycle to maintain normal physiological conditions. The molecular pathways that direct attenuation of hypoxia-induced proliferative signals in fibroblasts remain unknown.

PKC, a family of serine/threonine kinases, have been divided into three distinct groups: the conventional: calcium-, phospholipid-, and diacylglycerol-dependent PKC isozymes (cPKC, , , ); the novel: calcium-independent PKC isozymes (nPKC, , , ); and the atypical PKC isozymes (aPKC, , ), which are calcium-, phospholipid-, and diacylglycerol-independent (Nishizuka, 1992; Hug and Sarre, 1993). PKC can be activated directly or indirectly by a variety of important signaling molecules including ceramide (Powell et al., 2004), phosphatidic acid (Le Good et al., 1998), phosphoinositide 3-kinase lipid products and activation of the p21Ras pathway (Pal et al., 2001). PKC has emerged as a critical regulator of a number of cellular functions including proliferation, differentiation, and apoptosis (Hirai and Chida, 2003). This isozyme mediates proliferation in NIH3T3 cells (Berra et al., 1993; Kim et al., 1997), endothelial cells (Kent et al., 1995), and smooth muscle cells (Yano et al., 1999). In contrast, cytokine- and ceramide-induced activation of PKC leads to inhibition of proliferation and growth arrest in vascular smooth muscle cells, respectively (Bourbon et al., 2002; Hussain et al., 2002). Therefore, the biological functions of PKC in cellular responses are cell-type and stimulus specific. The mechanisms responsible for diverse physiological functions of PKC at the cellular level are not known.

A recent report has demonstrated that phosphorylation of the Na,K-ATPase ₁ subunit in lung alveolar epithelial cells under hypoxic conditions is mediated through PKC (Dada et al., 2003). Datta et al. (2004) have found that PKC participates in the activation of hypoxia-inducible factor-1 (HIF-1) by inhibiting the expression of asparagine hydroxylase (enzyme inhibitor of HIF-1), thereby promoting the transcription of hypoxia-inducible genes such as vascular permeability factor and vascular endothelial growth factor. Despite the importance of PKC in cellular signaling under hypoxic conditions, it is unknown whether PKC is a proliferative stimulator or suppressor in fibroblasts under hypoxic conditions.

Another set of protein kinases that plays an important role in transducing signal from intracellular PKC isozymes to the cell nucleus is MAP kinase family (Kim et al., 1997; Corbit et al., 2000; Mas et al., 2003). Previously, we have demonstrated that hypoxia induces transient activation of ERK1/2, one member of the MAP kinase family, and that ERK1/2 activation mediates replication of hypoxic fibroblasts (Das et al., 2001). PKC acts as an upstream regulator of ERK1/2 activation in response to various stimuli in different cell types (Hirai and Chida, 2003). However, the functional role of PKC in the regulation of hypoxia-induced activation of ERK1/2 in fibroblasts is not known.

Once activated, ERK1/2 can be rapidly inactivated through dephosphorylation by phosphatases known as dual specificity MAP kinase phosphatases (MKPs; Keyse and Emslie, 1992). The existence of at least eleven MKPs in mammals implies a considerable complexity in the regulation of MAP kinase signaling by these enzymes. Among these phosphatases, MKP-1 is encoded by an immediate early gene (Noguchi et al., 1993). Though MKP-1 is identified as a hypoxia-responsive gene (Laderoute et al., 1999; Seta et al., 2001; Liu et al., 2003), the role of this phosphatase in cellular responses under hypoxic conditions, is poorly understood. It is important to understand the mechanisms regulating MKP expression because the physiological functions of MKPs are largely determined by their expression patterns. Multiple pathways, e.g., ERK1/2, c-Jun N-terminal kinase (JNK), p38 MAP kinase and Ca²⁺-dependent pathways regulate MKP-1 expression (Reffas and Schlegel, 2000; Slack et al., 2001). PKC is also implicated as an important regulator in the expression of these phosphatases in various cell types (Stawowy et al., 2003). However, the signaling mechanisms that control hypoxia-stimulated MKP-1 expression in fibroblasts remain unknown.

The current study was undertaken to determine whether PKC activation and MKP-1 expression are required for the attenuation of ERK1/2 activation and proliferation in response to hypoxia in cultured vascular fibroblasts and whether PKC plays a role in the expression of MKP-1. Collectively, we hypothesized that PKC-induced up-regulation of MKP-1 mediates replication repressor activity of PKC to suppress ERK1/2 activation in fibroblasts upon hypoxic exposure.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGMENTS REFERENCES

 
Materials
Eagle's MEM, bromodeoxyuridine (BrdU), monoclonal antibody (mAb) against -tubulin and protease inhibitor cocktail were purchased from Sigma-Aldrich Chemical Company (St. Louis, MO). mAb against BrdU was obtained from Becton Dickinson Immunocytometry Systems (San Jose, CA). Fetal bovine serum (FBS) and porcine serum were from Gemini Bio-Products (Woodland, CA). Other antibodies were purchased from the following companies: polyclonal and monoclonal antibodies against PKC and PKC from Santa Cruz Biotechnology (Santa Cruz, CA), biotinylated anti-mouse IgG, streptavidin-conjugated Alexa 488- and Alexa 594-conjugated anti-rabbit IgG from Molecular Probes (Eugene, OR), phosphoERK1/2 and phosphoPKC/ (Thr410) from Cell Signaling (Beverly, MA). Polyclonal antibody against MKP-1, goat anti-rabbit and goat anti-mouse IgG conjugated with alkaline phosphatase were obtained from Santa Cruz and Upstate Biotechnology (Waltham, MA). Mounting medium containing 4',6-diamino-2-phenylindole dihydrochloride (DAPI) was obtained from Vector Laboratories (Burlingame, CA). Myristoylated pseudosubstrate peptide inhibitors of PKC and PKC classical and novel isozymes (PKC inhibitor) were purchased from Biomol (Plymouth, PA). Sodium vanadate was obtained from Fisher Scientific (Pittsburgh, PA). Additionally, PKC antisense phosphorothioate oligonucleotides were obtained from Integrated DNA Technologies (Skokie, IL) and Oligos Etc. (Wilsonville, OR). The rabbit PKC sequences used are as follows: rabbit PKC antisense (5'-GCTGCGCCGGCCTCACACG-3'); PKC scrambled antisense (5'-ACCCCGTCGGCCCATGGCG-3'). Plasmids containing phosphatase inactive mutant (Cys²⁵⁸ to Ser, pSG5-MKP-1-CS) of MKP-1 (MKP-1PI) was kindly provided by Dr. N. K. Tonks (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). Vector (pCMV6) containing constitutively active PKC (MyrPKC) was a gift of Dr. A. Toker (Harvard Medical School, Boston, MA).

Cell Culture
Main pulmonary artery adventitia was harvested from the 15-d-old neonatal control calves, carefully dissected free of blood vessels and fat under a dissecting microscope and then cut into small pieces. Fibroblasts from the tissue were isolated, characterized, and maintained according to previously described methods (Das et al., 2002). Cells were maintained in MEM, pH 7.4, supplemented with 10% FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, L-glutamine and incubated in a humidified atmosphere with 5% CO₂ at 37°C. Medium was changed twice per week and cells were harvested with trypsin (0.2 g/L) containing EDTA (0.5 g/L). Passages ranging from 3 to 12 were used for all experiments. The growth characteristics and the appearance of the cells, examined by light microscopy, did not change for the passages studied.

Cell Proliferation Assay
Cells were plated at a density of 20,000/well in a 24-well plate in 10% FBS-containing medium and growth arrested for 72 h according to the previously described method (Das et al., 2001). Quiescent cells were transiently transfected with Optimem medium (Invitrogen, Carlsbad, CA) by combining 2 µg/ml of lipofectin (Invitrogen) with DNA for 5-6 h at 37°C. We used MyrPKC, MKP-1PI, PKC antisense and scrambled oligonucleotides for different transfection experiments. The cells were allowed to recover from transfection either overnight (PKC antisense experiments) or 48 h (myrPKC and MKP-1PI experiments) and then exposed to either normoxia (21% O₂) or hypoxia (1% O₂) in the presence of BrdU (10 µM) for 24 h. For the hypoxic experiments, cells were placed either in sealed humidified gas chambers as previously described (Das et al., 2002) or Bactron X (Sheldon Manufacturing, Cornelius, OR) environmental hood. At the end of the treatment, cells were fixed with cold 0.3% H₂O₂ in methanol for 15 min, treated with 2 N HCl for 20 min, and then incubated with anti-BrdU antibody. VectaStain DAB kit (Vector Laboratories, Burlingame, CA) was used to visualize nuclei. The BrdU-positive and -negative nuclei were counted in five randomly chosen areas in each well and reported as a percent of control.

For the studies with PKC inhibitor and the inhibitor of PKC classical and novel isozymes, quiescent cells were preincubated with the pseudosubstrate peptide inhibitors for 1 h at 37°C and then exposed to either normoxia or hypoxia for 24 h in the presence of BrdU. Cells were processed for BrdU immunostaining as described above.

PKC Activation Assay
Cells were plated at a density of 0.5-1 x 10⁶ cells/100-mm Petri dish in medium containing 10% FBS, and growth was arrested for 72 h. Quiescent cells were exposed to hypoxia (1% O₂) for either 10 min or 24 h. Calyculin A (100 nM) was added to the cells to block the serine/threonine phosphatases. Fibroblasts were exposed to calyculin A for 10 min. For 24-h hypoxic exposure, cells were treated with calyculin A for last 10 min of the experimental period. At the end of the exposure, cells were harvested with lysis buffer (Cell Signaling) containing protease inhibitor cocktail (1:100), 0.1% SDS, and 1% sodium deoxycholate, freeze-thawed to disrupt cell membranes, and centrifuged at 10,000 x g. Lysates were collected and protein concentrations were estimated using the Bradford method (BIORAD, Hercules, CA). To evaluate PKC activation, 500-700 µg protein was incubated with anti-PKC antibody (1:200, monoclonal) overnight at 4°C and then with AG agarose beads (Santa Cruz Biotechnology and Upstate Biotechnology) for 2 h at 4°C with agitation. The antigen-antibody complex was isolated by centrifugation at 10,000 x g for 1 min. The supernatant was discarded and the beads were washed multiple times with lysis buffer. The recovered protein was separated by gel electrophoresis, transferred to polyvinylidene difluoride membranes (PVDF; Amersham Pharmacia Biotech, Piscataway, NJ), and probed with an antibody against phosphoThr-PKC (1:1000). Immunoreactivity was detected on x-ray film using chemiluminescent reagents (Amersham Pharmacia Biotech). Immunoprecipitation followed by immunoblotting using the anti-PKC antibody (1:1000) served as a control to monitor any changes in total PKC protein levels. Because the mAb against PKC may cross-react with PKC/ isozyme, immunoprecipitates were also immunoblotted against PKC using PKC-specific antibody (1:1000). Images of Western blots were scanned using EPSON TWAIN software with EPSON PERFECTION 2450 PHOTO scanner. Densitometric quantitation of the scanned bands was performed using the National Institutes of Health (NIH) Image 1.58 program. The area under the curve (AUC) for each band was determined and represents the band intensity in arbitrary units. The AUC at 0-h time was considered as 100% and percent increases in hypoxic fibroblasts were calculated with respect to 0 h.

Immunoblotting
For the examination of PKC and PKC expression in the presence of either MyrPKC or PKC-specific antisense oligonucleotides, vascular fibroblasts were plated at the density of 50,000-100,000 cells/well in a six-well plate in 10% FBS-containing medium and growth was arrested for 72 h. Quiescent cells were transiently transfected with the corresponding DNA according to the method described above for BrdU incorporation. Transfected cells were exposed to either normoxia or hypoxia for 24 h. Cells were harvested and processed for the evaluation of PKC and PKC expression at the end of the hypoxic exposure.

For the evaluation of ERK1/2 activation, cells were plated and growth-arrested according to the abovementioned method. In one set of experiments, the cells were transiently transfected with PKC scrambled and antisense oligonucleotides and exposed to either normoxia or hypoxia for 10 min and 24 h. In the other set of experiments, the cells were pretreated with PKC pseudosubstrate peptide inhibitor for 1 h and then exposed to either normoxia or hypoxia for 24 h. In both instances, the cells were harvested with lysis buffer containing protease inhibitor/deoxycholate/SDS and freeze-thawed, and lysates were recovered by centrifugation at 10,000 x g. Proteins were separated by gel electrophoresis, transferred to a PVDF membrane, and probed with anti-phosphoERK1/2 antibody (1:1000).

MKP-1 expression was also evaluated by immunoblotting techniques. Antibody against MKP-1 was used at a concentration of 1:200-1:1000. The time course of MKP-1 expression was determined at 0, 24, 48, and 72 h of hypoxic exposure. -Tubulin expression, used as an internal control, was detected by incubating the PVDF membrane with a mAb against -tubulin (1:1000).

Immunofluorescence Staining
Fibroblasts were plated in medium containing 10% FBS at a density of 20,000/well in eight-well glass chamber slides (Life Sciences, Denver, CO). After allowing to attach overnight, cells were growth-arrested with medium containing 0.1% FBS for 72 h. Quiescent cells were then exposed to either normoxia or hypoxia for 24 h. After treatment, cells were fixed with 4% paraformaldehyde at 4°C, permeabilized with 0.5% Triton X-100, blocked with porcine serum, and incubated with either an anti-PKC antibody (1:25 dilution) or anti-MKP-1 antibody (1:50 dilution). Immunofluorescent staining of PKC was completed by incubating cells with biotin-conjugated anti-mouse IgG (1:300) and streptavidin-conjugated Alexa 488 (1:2000). For MKP-1, antigen-antibody complexes were visualized by incubating the cells with Alexa 594-conjugated anti-rabbit secondary antibody (1:500). Nuclei were stained with Hoechst dye (1:1000). Slides were mounted with H1000 mounting medium. All steps were done at room temperature unless otherwise stated. Images were captured using an Olympus Infinity microscope (Melville, NY) coupled to a Photometrics Quantix cooled CCD camera (Tucson, AZ) and Deltavision digital deconvolution software.

Data Analysis
All data are expressed as arithmetic means ± SE; n equals the number of replicate wells per test condition in representative experiments. One- and two-way analyses of variance, followed by the Student-Newman-Keuls multiple-comparisons tests, were conducted within and between groups of data points. Data are considered significantly different if p 0.05.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGMENTS REFERENCES

 
PKC Attenuation Greatly Up-regulates Hypoxia-induced Proliferation of Fibroblasts
We previously demonstrated that hypoxia stimulates an increase in DNA synthesis, which results in cell division in vascular fibroblasts (Das et al., 2001). PKC is an important intracellular regulator of hypoxia-induced proliferation of fibroblasts (Das et al., 2000). To evaluate the role of atypical PKC isozyme in these proliferative responses, we first used the isozyme-specific myristoylated peptide inhibitor derived from the pseudosubstrate region. The peptide inhibitor mimics the substrate and maintains PKC in its inactive form (Hirai and Chida, 2003). Figure 1 depicts concentration-dependent effects of peptide inhibitor on the proliferative responses of fibroblasts. The inhibitor at low dose (1 µM) did not affect the DNA synthesis (Figure 1). However, BrdU incorporation in the quiescent cells was significantly increased in the presence of 10 µM inhibitor (Figure 1A). Hypoxia alone stimulated a twofold increase in DNA synthesis, whereas BrdU incorporation in hypoxia-exposed fibroblasts which were treated with 10 µM inhibitor was up-regulated by sevenfold (Figure 1A).

View larger version (18K): [in this window] [in a new window]   Figure 1. Myristoylated PKC pseudosubstrate peptide inhibitor stimulates DNA synthesis in vascular fibroblasts. (A) BrdU incorporation in hypoxic fibroblasts is greatly augmented by PKC inhibitor. For all the experiments where BrdU incorporation was evaluated, cells were plated at the density of 20 x 103/well in 24-well plates and growth-arrested with 0.1% FBS/MEM for 72 h. Quiescent fibroblasts were preincubated with different concentrations of PKC inhibitor at 37°C for 1 h and then exposed to either normoxia (21% O2) or hypoxia (1% O2) in the presence of BrdU (10 µM) for 24 h. At the end of the treatment, cells were fixed with cold 0.3% H2O2/methanol and processed for immunoperoxidase staining with anti-BrdU antibody. BrdU-positive and total nuclei were counted at five different randomly selected areas in individual well. n = 4 replicate wells. * p < 0.05 compared with normoxic control data. ** p < 0.05 compared with the hypoxic data. Similar results were obtained in three independent experiments with cell populations isolated from three independent animals. (B) PKC peptide inhibitor also up-regulates bFGF-stimulated DNA synthesis. Quiescent fibroblasts were treated with PKC inhibitor as mentioned above and then stimulated with bFGF (30 ng/ml) for 24 h in the presence of BrdU. n = 4 replicate wells. * p < 0.05 compared with the unstimulated control value. ** p < 0.05 compared with bFGF-stimulated data. Similar results were reproduced with at least two other cell populations.

To confirm the selectivity of PKC inhibitor-mediated stimulatory effects on BrdU incorporation, we also used a myristoylated pseudosubstrate peptide inhibitor, which was designed against classical and novel isozymes of PKC (PKC inhibitor). Neither hypoxia-induced nor bFGF-stimulated DNA synthesis was affected by PKC inhibitor (Figure 2, A and B). In contrast, and as shown independently above (Figure 1, A and B), PKC inhibitor selectively augmented hypoxia-stimulated and bFGF-induced BrdU incorporation (Figure 2, A and B). However, one can interpret, by contrasting hypoxia-induced and bFGF-stimulated BrdU incorporation in the presence of PKC inhibitor, that PKC attenuation unmasked proliferative responses in greater extent in hypoxic cells (Figure 1, 3-fold, and Figure 2, 7.6-fold, over hypoxia-induced DNA synthesis) than bFGF-stimulated fibroblasts (Figure 1, 1.3-fold, and Figure 2, 4-fold, compared with bFGF-stimulated proliferation). Therefore, functional role of PKC might be more critical during hypoxic exposure than bFGF-stimulated fibroblasts. Taken together, our data suggest that replicative up-regulation by myristoylated PKC pseudosubstrate peptide inhibitor is specific to this peptide and that PKC might act as a proliferation suppressing kinase in fibroblasts.

View larger version (17K): [in this window] [in a new window]   Figure 2. PKC inhibitor, but not PKC inhibitor of classical and novel isozymes, stimulates proliferation of vascular fibroblasts. (A) Hypoxia-induced DNA synthesis is selectively up-regulated by PKC inhibitor. Quiescent fibroblasts were preincubated with peptide inhibitors of PKC classical and novel isozymes (10 µM) and PKC isozyme (10 µM) at 37°C for 1 h. BrdU incorporation in both normoxic and hypoxic fibroblasts was evaluated. n = 4 replicate wells. * p < 0.05 compared with normoxic control results. ** p < 0.05 compared with hypoxic data. (B) PKC inhibitor of classical and novel isozymes does not affect bFGF-stimulated DNA synthesis. Cells were preincubated with inhibitors as mentioned above and then stimulated with bFGF (30 ng/ml) in the presence of BrdU (10 µM) for 24 h. n = 4 replicate wells. * p < 0.05 compared with nonstimulated control results. ** p < 0.05 compared with bFGF-induced data. Similar results were obtained from three independent experiments using fibroblasts isolated from three different animals.

To confirm the role of PKC as a replication repressor, we then used antisense oligonucleotides specific for the message encoding PKC. Transient transfection of the cells with PKC antisense oligonucleotides selectively reduced the PKC expression, but not the PKC levels (Figure 3, A and B). For detection of the PKC level in our cells by immunoblotting techniques, we used 4-5 times higher protein concentration than that used for the evaluation of the PKC levels. In addition, x-ray film was exposed up to 30 min for the detection of the PKC signal. Collectively, these observations suggest that a very low level of PKC is present in vascular fibroblasts. A recent report (Cogolludo et al., 2005) also supports the notion that PKC, but not PKC, is the major atypical isozyme of pulmonary vasculature.

View larger version (35K): [in this window] [in a new window]   Figure 3. PKC attenuation with antisense oligonucleotides stimulates BrdU incorporation in vascular fibroblasts. (A) PKC expression is blocked by antisense oligonucleotides in fibroblasts. For all the transfection experiments, cells were plated at a density of 50-100 x 103/well in six-well plates in 10% FBS/MEM and growth-arrested with 0.1% FBS/MEM for 72 h. Quiescent cells were transiently transfected with PKC scramble and antisense oligonucleotides. After overnight recovery from transfection, cells were harvested with the lysis buffer. Whole cell lysates were processed for immunoblot analysis with anti-PKC mAb. (B) PKC antisense oligonucleotides have no effects on PKC expression. The abovementioned cell lysates were processed for Western blot analysis for PKC detection using mAb against PKC. (C) BrdU incorporation in fibroblasts is greatly up-regulated by PKC antisense oligonucleotides. Quiescent cells were transiently transfected with PKC scramble and antisense oligonucleotides. Transfected cells were incubated at 37°C for overnight. Then BrdU (10 µM) was added to the cells and exposed to either normoxia or hypoxia for 24 h at 37°C. n = 4 replicate wells. * p < 0.05 compared with the data in the presence of scramble oligonucleotides under normoxic conditions. Similar results were reproduced in at least two different cell populations isolated from two different animals.

Proliferative responses of fibroblasts in the presence of PKC antisense oligonucleotides were then evaluated by measuring the BrdU incorporation. Marked increase in DNA synthesis was observed upon attenuation of PKC expression with antisense oligonucleotides in normoxic fibroblasts (Figure 3C). Hypoxia stimulated BrdU incorporation in fibroblasts both in the presence of scrambled and PKC-specific antisense oligonucleotides (Figure 3C). Equal magnitude in the up-regulation of DNA synthesis upon blockade of PKC expression with antisense oligonucleotides under both normoxic and hypoxic conditions suggests that proliferative responses are primarily regulated by PKC-mediated signaling pathways in fibroblasts in response to hypoxic exposure. Collectively, these results further support the role of PKC as a proliferative repressor for vascular fibroblasts.

PKC Overexpression Attenuates Proliferation of Hypoxic Fibroblasts
The myristoylated pseudosubstrate peptide inhibitor can block the activation of both PKC and PKC because sequence homology exists in the pseudosubstrate region between these two atypical isozymes (Toker, 1998). Therefore, to confirm that the proliferation stimulatory effects of the inhibitor (Figures 1 and 2) are due to PKC inhibition and not attenuation of PKC activity, PKC was overexpressed in fibroblasts by transient transfection with constitutively active PKC (MyrPKC). Increased expression of PKC, but not PKC, in the presence of MyrPKC was confirmed by Western blot analysis (Figure 4, A and B).

View larger version (29K): [in this window] [in a new window]   Figure 4. PKC overexpression attenuates DNA synthesis in vascular fibroblasts. (A) PKC expression is augmented in fibroblasts transfected with constitutively active PKC (MyrPKC). Quiescent cells were transiently transfected with vector containing MyrPKC and empty vector (PCMV5). After 48 h of transfection, cells were exposed to either normoxia or hypoxia for 24 h and harvested with lysis buffer. Cell lysates were processed for PKC detection by immunoblot analysis. (B) MyrPKC does not affect PKC expression in fibroblasts. In the abovementioned cell lysates, PKC expression was evaluated by Western blot analysis using PKC-specific mAb. (C) BrdU incorporation in hypoxic fibroblasts is attenuated by MyrPKC. Transfected fibroblasts were exposed to either normoxia or hypoxia in the presence of BrdU for 24 h. n = 4 replicate wells. * p < 0.05 compared with PCMV5-transfected normoxic results. ** p < 0.05 compared with the results of PCMV5-transfected hypoxic cells. Similar results were obtained from three independent experiments using fibroblasts isolated from three different animals.

We then evaluated BrdU incorporation in the presence of MyrPKC. Hypoxia induced a 2.5-fold up-regulation of BrdU incorporation in vector-transfected cells (Figure 4C). However, marked down-regulation (6-fold) in DNA synthesis was observed in PKC-overexpressing cells compared with the vector-transfected fibroblasts under hypoxic conditions (Figure 4C). These data strongly suggest that PKC acts as a proliferative repressor in fibroblasts under hypoxic conditions.

View larger version (26K): [in this window] [in a new window]   Figure 5. Hypoxia induces PKC phosphorylation in vascular fibroblasts. (A and B) Phosphorylation of the Thr410 residue of PKC is increased by hypoxic exposure. Growth-arrested cells were exposed to hypoxia for 10 min and 24 h. Whole cell lysates (0.5-0.7 mg total protein) were immunoprecipitated with monoclonal anti-PKC antibody and the immunocomplexes were analyzed by immunoblot analysis with antibodies specific for either phosphoPKC (A) or total PKC (polyclonal; B). Representative immunoblot of three independent experiments is shown. (C) Quantitative data of hypoxia-induced PKC phosphorylation in vascular fibroblasts. * p < 0.05 compared with the data of normoxic condition.

Hypoxia Up-regulates PKC Phosphorylation

We used an mAb directed toward the C-terminus of PKC to immunoprecipitate the isozyme. This antibody may cross-react with the other atypical isozyme, i.e., PKC. To rule out that possibility, PKC immunoprecipitates were immunoblotted for PKC. PKC signal was not detected in the PKC precipitate (our unpublished observation), suggesting the antibody against PKC does not cross-react with PKC in vascular fibroblasts. Therefore, our data suggest that hypoxia stimulates phosphorylation of PKC (Thr410) in vascular fibroblasts and is consistent with our previous observation of hypoxia-induced increase in PKC-specific activity in fibroblasts (Das et al., 2000).

View larger version (37K): [in this window] [in a new window]   Figure 6. Hypoxia stimulates ERK1/2 phosphorylation in vascular fibroblasts. (A and B) ERK1/2 phosphorylation is greatest in acute (10 min) hypoxia-exposed fibroblasts. Quiescent cells were exposed to hypoxia for 10 min and 24 h and harvested with lysis buffer. Whole cell lysates were processed for immunoblot analysis. PhosphoERK1/2 (A) and total ERK1/2 (B) were evaluated using phosphoERK1/2- and total ERK1/2-specific antibodies. Representative blots of four independent experiments are shown here. (C) Quantitative data of hypoxia-stimulated ERK1/2 phosphorylation in vascular fibroblasts. * p < 0.001 compared with normoxic results. ** p < 0.001 compared with data of normoxic and acute (10 min) hypoxia-exposed conditions.

PKC Inhibition Up-regulates ERK1/2 Phosphorylation
To evaluate a possible role of PKC in hypoxia-induced ERK1/2 activation, ERK1/2 phosphorylation was examined upon blockade of PKC expression. First, attenuation of PKC level with antisense oligonucleotides was confirmed by Western blot analysis (Figure 7A). Acute (10 min) hypoxia-induced ERK1/2 phosphorylation was observed in the presence of scrambled oligonucleotides (Figure 7B). To our surprise, ERK1/2 were also significantly phosphorylated in both normoxic and hypoxic fibroblasts upon down-regulation of PKC expression with antisense oligonucleotides, implicating that PKC might be a suppressor of hypoxia-induced ERK1/2 phosphorylation (Figure 7B). The quantitative data of acute hypoxia-induced ERK1/2 activation in the presence of PKC antisense and scrambled oligonucleotides are presented in Figure 7D.

View larger version (60K): [in this window] [in a new window]   Figure 7. PKC attenuation induces persistent ERK1/2 activation in vascular fibroblasts. (A) Transient transfection of quiescent fibroblasts with PKC scramble and antisense oligonucleotides induced selective blockade of PKC expression, but did not alter PKC levels. (B) ERK1/2 phosphorylation is increased by PKC antisense oligonucleotides in acute (10 min) hypoxia-exposed cells. Transfected cells were exposed to either normoxia or hypoxia for 10 min. Total protein was extracted with lysis buffer. Western blots were performed on the extracts using an anti-phosphoERK1/2 antibody and anti-ERK1/2 antibody to examine the levels of phosphorylated and total ERK1/2. Similar results were obtained from three independent experiments. Representative immunoblots of phosphoERK1/2 and total ERK1/2. (C) In prolonged (24 h) hypoxia-exposed fibroblasts, PKC blockade results in persistent ERK1/2 phosphorylation. Transfected fibroblasts were exposed to either normoxia or hypoxia for 24 h. At the end of the experimental period, whole cell lysates were processed for immunoblot analysis with anti-phosphoERK1/2 and total ERK1/2 antibodies. (D) Quantitative measurement of acute (10 min) hypoxia-induced ERK1/2 phosphorylation in the presence of PKC scramble and antisense oligonucleotides. * p < 0.05 compared with the results of normoxic cells transfected with scramble oligonucleotides. (E) Quantitative measurement of ERK1/2 phosphorylation upon PKC attenuation with antisense oligonucleotides in prolonged (24 h) hypoxia-stimulated fibroblasts. * p < 0.05 compared with data of the normoxic cells that were transfected with scramble oligonucleotides. ** p < 0.05 compared with the results of hypoxic fibroblasts transfected with scramble oligonucleotides.

The role of PKC on ERK1/2 dephosphorylation was further investigated using myristoylated PKC pseudosubstrate peptide inhibitor. Significant up-regulation of ERK1/2 phosphorylation has occurred in the presence of PKC inhibitor (Figure 8A). We then used PKC inhibitor to evaluate phopshoERK1/2 localization in response to hypoxic stimulation. We were not able to detect any signal for activated ERK1/2 in quiescent fibroblasts by immunofluorescent staining (Figure 8C). In cells exposed to prolonged hypoxia (24 h), phosphoERK1/2 was expressed as distinct spots outside the nucleus (Figure 8C). However, in the presence of the PKC inhibitor, the intensity of phosphoERK1/2 immunofluorescent staining was strikingly enhanced (Figure 8C). Also, phosphoERK1/2 was compartmentalized in the nucleus as well as in the cytoplasm of hypoxic fibroblasts upon PKC inhibition (Figure 8C). PhosphoERK1/2 must be inside the nuclear compartment to initiate cellular proliferative responses (Pouyssegur et al., 2002). Therefore, our data suggest that PKC inhibition initiates exuberant replication of hypoxic fibroblasts (Figures 1 and 2) by permitting persistent nuclear localization of phosphoERK1/2 in hypoxic cells. Taken together the data, we conclude that PKC is the regulatory switch of ERK1/2 dephosphorylation status in fibroblasts in response to hypoxic exposure.

View larger version (41K): [in this window] [in a new window]   Figure 8. PKC pseudosubstrate peptide inhibitor stimulates prolonged ERK1/2 phosphorylation in the nuclear compartment of vascular fibroblasts. (A) Western blot analysis of phosphoERK1/2 in the presence of PKC inhibitor. Quiescent fibroblasts were preincubated with PKC inhibitor (10 µM) for 1 h at 37°C, exposed to either normoxia or hypoxia for 24 h, and then harvested with lysis buffer. Whole cell lysates were separated by Western blot analysis and probed with anti-phosphoERK1/2 and total ERK1/2 antibodies. Similar results were obtained in three different experiments. Cells used for the three experiments were isolated from three different animals. A representative blot of phosphoERK1/2 is shown. (B) Representative blot of total ERK1/2. (C) PKC inhibition induces nuclear localization of activated ERK1/2 in fibroblasts. Representative photographs of phosphoERK1/2 compartmentalization in hypoxic fibroblasts. Cells were plated at the density of 20 x 103/well/0.5 ml of 10% FBS/MEM in eight-well glass chamber slides, allowed to attach overnight, and then growth-arrested with 0.1% FBS/MEM for 72 h. Fibroblasts were incubated with PKC inhibitor and then exposed to either normoxia or hypoxia according to the abovementioned method. At the end of the treatment, cells were fixed with cold 4% paraformaldehyde and indirect immunofluorescent staining of phosphoERK1/2 was performed. Nuclei were stained with Hoechst dye. Magnification, x100. Similar results were obtained in two other experiments using different cell populations.

View larger version (33K): [in this window] [in a new window]   Figure 9. MKP-1 regulates ERK1/2 dephosphorylation in vascular fibroblasts. (A and B) Significant up-regulation in phosphoERK1/2 levels is observed in the presence of sodium vanadate, an antagonist of tyrosine phosphatases. Growth-arrested cells were preincubated with sodium vanadate (200 µM) for 24 h. Whole cell lysates were separated by Western blot analysis and probed with anti-phosphoERK1/2 and total ERK1/2 antibodies. Similar results were obtained in another independent experiment using different cell populations. (C and D) MKP-1 is overexpressed in fibroblasts transfected with phosphatase inactive MKP-1 (MKP-1PI). Quiescent fibroblasts were transiently transfected with MKP-1PI or empty vector. Cells were harvested with lysis buffer after 48 h of transfection. Whole cell lysates were separated by immunoblot analysis for the evaluation of MKP-1 and tubulin expression. (E and F) PhosphoERK1/2 levels are greatly higher in the cells transfected with MKP-1PI than in those transfected with empty vector. MKP-1PI- and empty vector-transfected cells were exposed to either normoxia or hypoxia (10 and 60 min). Proteins from the cell lysates were separated by Western blot analysis and probed with anti-phosphoERK1/2 and total ERK1/2 antibodies. Similar results were obtained in three different experiments using three different cell populations.

Hypoxia-induced Increase in MKP-1 Levels Represses Fibroblast Proliferation
MKP-1 is a hypoxia-responsive gene (Laderoute et al., 1999; Seta et al., 2001; Liu et al., 2003). To evaluate the effects of hypoxia on MKP-1 expression in vascular fibroblasts, quiescent cells were exposed to hypoxia (1% O₂) for different lengths of time and MKP-1 expression was examined by immunoblot analysis. Growth-arrested cells expressed a significant amount of constitutive MKP-1 protein (Figure 10A). After 24 h of hypoxic exposure, MKP-1 levels were greatly increased in the cells (Figure 10A). MKP-1 is an early response tumor suppressor gene and has a rapid turnover (Noguchi et al., 1993). MKP-1 might accumulate over time in both normoxic as well as hypoxic fibroblasts (Figure 10A). In spite of the high levels of MKP-1 under normoxic conditions, hypoxic cells always had greater MKP-1 levels (Figure 10A). Equal protein loading among the samples was verified by immunoblotting with an antibody against tubulin (Figure 10). Therefore, these data suggest that hypoxia up-regulates MKP-1 expression in fibroblasts.

View larger version (29K): [in this window] [in a new window]   Figure 10. Hypoxia-induced increase in MKP-1 levels terminates proliferation of hypoxic fibroblasts. (A) Hypoxia up-regulates MKP-1 expression. Quiescent fibroblasts were exposed to either normoxia or hypoxia for 24-72 h and harvested with lysis buffer. Western blot analysis of the cell lysates was performed using anti-MKP-1 and tubulin antibodies. Representative blot of the three independent experiments is shown. (B) Transfection of fibroblasts with MKP-1PI stimulates BrdU incorporation in the cells. Growth-arrested cells were transiently transfected with empty vector and MKP-1PI. After 48 h of transfection, cells were exposed to either normoxia or hypoxia in the presence of BrdU for 24 h. n = 4 replicate wells. * p < 0.05 compared with vector transfected normoxic results. ** p < 0.05 compared with the vector-transfected hypoxic data. Similar results were obtained from three independent experiments using fibroblasts from three different animals.

PKC Regulates MKP-1 Expression
The strong parallel between proliferative up-regulation and persistent ERK1/2 phosphorylation with PKC attenuation (Figures 1, 2, 7, and 8) and MKP-1 blockade (Figures 9 and 10) suggest that PKC might direct ERK1/2 dephosphorylation events by regulating MKP-1. Therefore, the role of PKC in MKP-1 expression was first evaluated using PKC antisense oligonucleotides. In the presence of scrambled oligonucleotides, MKP-1 levels were up-regulated in hypoxic fibroblasts (Figure 11A). PKC blockade with antisense oligonucleotides induced marked reduction in MKP-1 expression (Figure 11A). Preincubation of fibroblasts with myristoylated PKC pseudosubstrate peptide inhibitor also resulted in complete blockade of MKP-1 expression under both normoxic and hypoxic conditions (our unpublished observation).

View larger version (52K): [in this window] [in a new window]   Figure 11. PKC regulates MKP-1 expression in vascular fibroblasts. (A) PKC blockade attenuates MKP-1 expression. Quiescent fibroblasts were transiently transfected with PKC scramble and antisense oligonucleotides. After allowing overnight recovery from transfection, cells were exposed to either normoxia or hypoxia for 24 h. Whole cell lysates were separated by gel electrophoresis and probed with anti-MKP-1, PKC, and tubulin antibodies. (B) MyrPKC stimulates MKP-1 expression in fibroblasts. Growth-arrested fibroblasts were transiently transfected with PCMV5 and MyrPKC. Cells were harvested with lysis buffer after 48 h of transfection. MKP-1, PKC and tubulin were detected in the cell lysates by Western blot analysis. Similar results were obtained in three independent experiments using three different fibroblast populations isolated from three different animals.

MKP-1 regulation by PKC was further confirmed by using MyrPKC. Growth-arrested fibroblasts were transiently transfected with empty vector (PCMV5) and MyrPKC. PKC overexpression stimulated an increase in MKP-1 levels in fibroblasts (Figure 11B). Collectively, these data suggest that PKC regulates MKP-1 expression in vascular fibroblasts.

PKC and MKP-1 Colocalize in the Nucleus of Vascular Fibroblasts
To evaluate the localization of PKC and MKP-1, both normoxic and hypoxia-exposed (24 h) cells were subjected to double immunofluorescent staining for PKC and MKP-1. Under normoxic conditions, punctate staining pattern of both MKP-1 and PKC was detected in the nuclear compartment of fibroblasts (Figure 12A). Intensity of the immunoreactivity of both PKC and MKP-1 was enhanced in the nuclear compartment of hypoxic fibroblasts (Figure 12B).

View larger version (21K): [in this window] [in a new window]   Figure 12. MKP-1 and PKC colocalize in the nuclear compartment of vascular fibroblasts. (A) Representative photographs of MKP-1 and PKC in normoxic fibroblasts. Quiescent cells were fixed with cold 4% paraformaldehyde and permeabilized with 0.5% Triton X-100. Double immunofluorescent staining was performed with anti-MKP-1 and PKC antibodies. Magnification, x100. (B) Representative photographs of nuclear localization of MKP-1 and PKC in hypoxic fibroblasts. Growth-arrested cells were exposed to hypoxia for 24 h. At the end of hypoxic exposure, MKP-1 and PKC were visualized by double immunofluorescent staining. (C) Nuclear staining of PKC is abolished in the presence of PKC peptide and anti-PKC antibody. To confirm the specificity of nuclear PKC staining, the PKC peptide was preincubated with the anti-PKC antibody overnight at 4°C. Immunofluorescent staining of PKC was performed with this antigen-antibody complex. (D) Myristoylated PKC pseudosubstrate peptide inhibitor induces disorganization of defined nuclear localization of MKP-1 in fibroblasts. Growth-arrested fibroblasts were preincubated with PKC-specific peptide inhibitor (10 µM) for 1 h at 37°C and then exposed to either normoxia or hypoxia for 24 h. At the end of the treatment, cells were fixed and processed for indirect immunofluorescent staining of MKP-1. Similar results were reproduced in two other fibroblast populations. Magnification, x100. n = 4 replicate wells. A representative micrograph of the three independent experiments is shown in each case.

Fibroblasts were then preincubated with PKC-specific peptide inhibitor and exposed to either normoxia or hypoxia for 24 h. MKP-1 immunofluorescent staining in the nucleus was disrupted upon PKC inhibition (Figure 12D). Nuclear effects of myristoylated PKC pseudosubstrate peptide inhibitor are neither surprising nor unique for this cell type. Theodore et al. (1995) have reported that myristoylated PKC pseudosubstrate peptide inhibitor is capable of translocating across biological membranes to accumulate in all compartments of neuronal cells. Therefore, our results show that MKP-1 expression is tightly regulated by PKC in the nucleus of vascular fibroblasts.

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGMENTS REFERENCES

 
Despite our previous studies on signaling pathways that mediate hypoxia-induced proliferation of fibroblasts (Das et al., 2000 and 2001), it remains unclear how replication suppressors, which simultaneously coexist with proliferative stimulators, work collaboratively to attenuate normal proliferation of hypoxic fibroblasts. In the present study, we report for the first time that PKC is the master regulator of hypoxia-induced ERK1/2 dephosphorylation events through the regulation of MKP-1 expression and thereby limits proliferation of hypoxic fibroblasts (Figure 13). PKC attenuation leads to striking up-regulation in proliferation as well as ERK1/2 phosphorylation in hypoxic fibroblasts. In contrast, PKC overexpression induces a significant down-regulation of replication in hypoxic cells. PKC regulates hypoxia-induced MKP-1 expression in fibroblasts. MKP-1 blockade mimics the results of PKC attenuation on hypoxia-stimulated ERK1/2 phosphorylation and proliferation. These results strongly support the idea that PKC acts as a replication repressor through its regulation of MKP-1 expression in hypoxic fibroblasts.

View larger version (18K): [in this window] [in a new window]   Figure 13. Schematic diagram: role of PKC in the termination of proliferation of hypoxic fibroblasts through the regulation of ERK1/2 dephosphorylation and MKP-1 expression.

Our data in vascular fibroblasts contrast with the majority of published reports where PKC is described as a proliferative mediator in a variety of cells (Hirai and Chida, 2003). Recently, Braun and Mochly-Rosen (2003) have demonstrated that PKC is required for TGF1-induced proliferation of neonatal primary cardiac fibroblasts. PKC attenuation also inhibits platelet-derived growth factor (PDGF)-induced proliferation of human airway smooth muscle cells (Carlin et al., 2000). However, a recent report also demonstrates that PKC blockade does not inhibit rabbit vascular smooth muscle cell proliferation (Hussain et al., 2002). In fact, PKC inhibition increases growth factor- and cytokine-induced proliferation, which supports the notion that PKC is an antiproliferative kinase under specific circumstances and is in agreement with our results describing the role of PKC as proliferative repressor of hypoxic fibroblasts. Therefore, the role of PKC in proliferation is not only cell type specific, but also species specific and hence, the function of this particular atypical isozyme in cellular proliferative responses requires more rigorous characterization.

PKC plays an important functional role in mitogenic signaling by initiating the activation of the downstream MAP kinases such as MEK and ERK family proteins (Berra et al., 1993). Activation of the ERK cascade is known to be associated with cellular proliferation (Chang et al., 2003). Previously, we have also reported that proliferation of hypoxic fibroblasts is regulated by hypoxia-induced ERK1/2 activation (Short et al., 2004). However, in the present study, PKC attenuation results in persistent ERK1/2 phosphorylation, which contributes to the exuberant proliferation of hypoxic fibroblasts. Another important point is that PKC blockade induces accumulation of activated ERK1/2 in the nucleus, which is consistent with the fact that presence of activated ERK1/2 in the nucleus is necessary for the induction of cell proliferation (Pouyssegur et al., 2002). PKC-induced termination of ERK phosphorylation observed in the present studies is in contrast to the previously published reports demonstrating that PKC is the upstream kinase of MEK and ERK in other cell types (Berra et al., 1993). Also, in spite of the similar increases in proliferation of our cells and rabbit vascular smooth muscle cells (Hussain et al., 2002) upon PKC inhibition, the role of PKC in ERK1/2 activation is different between the two cell types. In the vascular fibroblasts, PKC is the master regulatory switch of ERK1/2 dephosphorylation events, whereas in rabbit smooth muscle cells ERK1/2 activation is independent of PKC activation (Hussain et al., 2002). Therefore, the functional role of PKC in the regulation of ERK1/2 activation upon a stimulus is a highly cell- and condition-specific event.

Because of the critical importance of ERK1/2 in cellular signaling, the activities of ERKs must be tightly regulated and this can be achieved by ERK-specific phosphatases, e.g., MKP family members. There are at least 11 MKPs in mammals, which imply the existence of a complex regulatory network for MAP kinase signaling. MKPs differ by properties such as tissue-specific expression, differential regulation in response to various stimuli, distinct subcellular localization and substrate specificity. MKP-1 has also been identified as a hypoxia-responsive gene in a variety of cell types (Keyse and Emslie, 1992; Noguchi et al., 1993; Laderoute et al., 1999) and is an immediate-early gene product, characterized by rapid transcriptional induction after MAP kinase family activation, short half-life, and rapid destruction by the 26S proteasome (Keyse and Emslie, 1992; Keyse, 1995). MKP-1 participates in the determination of the kinetics and thus the cellular outcome of MAP kinase signaling (e.g., proliferation vs. differentiation; Charles et al., 1993; Nishida and Gotoh, 1993; and survival vs. apoptosis; Xaus et al., 2001). The interaction between MKP-1/MAP kinase signaling also exhibits cell type specificity (Zhang et al., 2003).

In the present study, hypoxia-induced up-regulation of MKP-1 provides a novel mechanism, to account for the inhibitory effects of PKC on ERK1/2 phosphorylation and proliferation in hypoxic fibroblasts. Marked prolongation of ERK1/2 phosphorylation in cells treated with either PKC antisense oligonucleotides or myristoylated PKC peptide inhibitor correlates with the inhibition of MKP-1 expression upon PKC attenuation. Consequently, our results allow us to conclude that PKC is the suppressor of ERK1/2 phosphorylation by regulating MKP-1 expression. Prolonged activation of PKC in hypoxic fibroblasts (Figure 5) might be required by the system to maintain the level of MKP-1 upon hypoxic exposure. MKP-1 overexpression inhibits ERK-regulated reporter gene expression, Ras-induced DNA synthesis, and growth-factor-stimulated entry into the S phase in fibroblasts (Brunet et al., 1995). As a result, MKP-1 expression constitutes a control mechanism for attenuation of mitogenic signaling pathways. Our data further suggest that PKC-mediated MKP-1 expression plays a crucial role in the proper termination of ERK1/2 activation during the hypoxic exposure and contributes to "switching off" the signals directing the proliferation of hypoxic fibroblasts.

Evidence is accumulating to indicate that PKC is associated with nuclear events both in resting cells as well as in actively dividing cells (Capitani et al., 1987; Chiarugi et al., 1990; Buchner et al., 1992; Neri et al., 1994). In the present study, PKC localization in the nuclear compartment is consistent with the report demonstrating its expression in the nuclei of unstimulated adipocytes (Lacasa et al., 1995). Stimulation of the adipocytes with insulin or serum caused a rapid increase in nuclear PKC activity, suggesting that PKC could directly phosphorylate structural and/or regulatory nuclear proteins. Nucleolin and heterogeneous nuclear ribonucleoprotein are the substrates of PKC, suggesting that PKC may play an important role in nuclear signal transduction (Tuteja and Tuteja, 1998). Nuclear PKC might be the critical mediator of the hypoxic responses in fibroblasts because PKC transactivates HIF-1 by blocking the expression of a factor inhibiting HIF-1 in renal cancer cells (Datta et al., 2004). Interestingly, MKP-1 colocalizes with PKC in the nuclear compartment of fibroblasts. PKC association with MKP-1 in the nucleus may constitute the critical replication repressor system in fibroblasts.

Manipulation of PKC levels, either by inhibition or overexpression, leads to subsequent alteration in MKP-1 levels, suggesting that PKC tightly regulates MKP-1 expression in fibroblasts. MKP-1 expression is also regulated by PKC, albeit by a different isozyme, PKC, in bone marrow macrophages (Valledor et al., 2000). In H41E rat hepatoma cells, insulin-induced MKP-1 expression is blocked by the myristoylated PKC pseudosubstrate peptide inhibitor (Lornejad-Schafer et al., 2003). However, in that report PKC-mediated MKP-1 expression is not correlated with any cellular response. We believe that our data are the first demonstration of nuclear colocalization of MKP-1 and PKC, which together function as terminators of proliferative signals in hypoxic fibroblasts. Our future studies will focus on evaluating the mechanism of PKC-mediated regulation of MKP-1 expression in vascular fibroblasts.

Excessive proliferation of fibroblasts is associated with a number of vascular diseases (Stenmark et al., 1987; Stenmark and Mecham, 1997; Stenmark et al., 2000; Rey and Pagano, 2002), asthma, chronic obstructive pulmonary diseases, pulmonary fibrosis (Zhong et al., 2005), and also cancer (Bhowmick et al., 2004). Multiple factors including growth factors, cytokines, mechanical stress, hypoxia, neurotransmitters, and hormones are believed to contribute to the processes leading to fibroblast proliferation (Sartore et al., 2001), wherein PKC might serve as a common second messenger mediating the termination signals for proliferative responses. One of the primary steps in the orchestrated "emergency stop" cascade may be the up-regulation of MKP-1 expression that dephosphorylates ERK1/2 and consequently attenuates proliferation. PKC exerts its suppressing effect on ERK activation and proliferation in vascular fibroblasts primarily through interactions that involve MKP-1. Thus, we postulate that the balance between PKC-mediated MKP-1 expression and ERK1/2 activities stimulated by hypoxia is critical for maintaining cellular homeostasis. Further understanding of the mechanisms by which hypoxia stimulates the PKC-mediated induction of MAP kinase phosphatase might lead to strategies for the prevention and treatment of fibroproliferative diseases resulting from chronic hypoxic exposure.

	ACKNOWLEDGMENTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGMENTS REFERENCES

 
We thank Steve Hofmeister and Sandi Walchak for harvesting bovine pulmonary artery tissue and Dr. Michael Zawada, Dr. Mary Reyland, and Dr. Raphael Nemenoff for critical review of the manuscript. This study was supported by National Heart, Lung, and Blood Institute Grant HL 64917 (M. Das), HL57144-09, and HL14985-33 (K.R. Stenmark).

	Footnotes

 
This article was published online ahead of print in MBC in Press (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E05-09-0869) on February 8, 2006.

Address correspondence to: Mita Das (Mita.Das{at}uchsc.edu).

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGMENTS REFERENCES

 
Atamas, S. P. ((2002). ). Complex cytokine regulation of tissue fibrosis. Life Sci. 72, , 631-643.[CrossRef][Medline]

Berra, E., DiazMeco, M. T., Dominguez, I., Municio, M. M., Sanz, L., Lozano, J., Chapkin, R. S., and Moscat, J. ((1993). ). Protein kinase C zeta isoform is critical for mitogenic signal transduction. Cell 74, , 555-563.[CrossRef][Medline]

Bhowmick, N. A., Neilson, E. G., and Moses, H. L. ((2004). ). Stromal fibroblasts in cancer initiation and progression. Nature 432, , 332-337.[CrossRef][Medline]

Bourbon, N. A., Sandirasegarane, L., and Kester, M. ((2002). ). Ceramide-induced inhibition of Akt is mediated through protein kinase C zeta: implications for growth arrest. J. Biol. Chem. 277, , 3286-3292.[Abstract/Free Full Text]

Braun, M. U., and Mochly-Rosen, D. ((2003). ). Opposing effects of - and -protein kinase C isozymes on cardiac fibroblast proliferation: use of isozyme-selective inhibitors. J. Mol. Cell Cardiol. 35, , 895-903.[CrossRef][Medline]

Brunet, A., Brondello, J. M., L'Allemain, G., Lenormand, P., McKenzie, F., Pages, G., and Pouyssegur, J. ((1995). ). MAP kinase module: role in the control of cell proliferation. CR Seances Soc. Biol. Fil. 189, , 43-57.[Medline]

Buchner, K., Otto, H., Hilbert, R., Lindschau, C., Haller, H., and Hucho, F. ((1992). ). Properties of protein kinase C associated with nuclear membranes. Biochem. J. 286, , 369-375.

Capitani, S., Girard, P. R., Mazzei, G. J., Kuo, J. F., Berezney, R., and Manzoli, F. A. ((1987). ). Immunochemical characterization of protein kinase C in rat liver nuclei and subnuclear fractions. Biochem. Biophys. Res. Commun. 142, , 367-375.[CrossRef][Medline]

Carlin, S., Poronik, P., Cook, D. L., Carpenter, L., Biden, T. J., Johnson, P.R.A., and Black, J. L. ((2000). ). An antisense of protein kinase C-zeta inhibits proliferation of human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 23, , 555-559.[Abstract/Free Full Text]

Chang, F., Steelman, L. S., Shelton, J. G., Lee, J. T., Navolanic, P. M., Blalock, W. L., Franklin, R., and McCubrey, J. A. ((2003). ). Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int. J. Oncol. 22, , 469-480.[Medline]

Charles, C. H., Sun, H., Lau, L. F., and Tonks, N. K. ((1993). ). The growth factor-inducible immediate-early gene 3CH134 encodes a protein-tyrosine-phosphatase. Proc. Natl. Acad. Sci. USA 90, , 5292-5296.[Abstract/Free Full Text]

Chiarugi, V., Magnelli, L., Pasquali, F., Vannucchi, S., Bruni, P., Quattrone, A., Basi, G., Capaccioli, S., and Ruggiero, M. ((1990). ). Transformation by ras oncogene induces nuclear shift of protein kinase C. Biochem. Biophys. Res. Commun. 173, , 528-533.[CrossRef][Medline]

Cho, Y., and Ziboh, V. A. ((1995). ). Nutritional modulation of guinea pig skin hyperproliferation by essential fatty acid deficiency is associated with selective down regulation of protein kinase C-beta. J. Nutr. 125, , 2741-2750.[Abstract/Free Full Text]

Cogolludo, A., Moreno, L., Lodi, F., Tamargo, J., and Perez-Vizcaino, F. ((2005). ). Postnatal maturational shift from protein kinase C zeta and voltage-gated K⁺ channels to RhoA/Rho kinase in pulmonary vasoconstriction. Cardiovasc. Res. 66, , 84-93.[Abstract/Free Full Text]

Corbit, K. C., Soh, J. W., Yoshida, K., Eves, E. M., Weinstein, I. B., and Rosner, M. R. ((2000). ). Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. Mol. Cell. Biol. 20, , 5392-5403.[Abstract/Free Full Text]

Dada, L., Chandel, N. S., Ridge, K. M., Pedemonte, C., Bertorello, A. M., and Sznajder, J. I. ((2003). ). Hypoxia-induced endocytosis of Na, K-ATPase in alveolar epithelial cells is mediated by mitochondrial reactive oxygen species and protein kinase C-zeta. J. Clin. Invest. 111, , 1057-1064.[CrossRef][Medline]

Das, M., Dempsey, E. C., Bouchey, D., Reyland, M. R., and Stenmark, K. R. ((2000). ). Chronic hypoxia induces exaggerated growth responses in pulmonary artery adventitial fibroblasts: potential contribution of specific protein kinase C isozymes. Am. J. Respir. Cell Mol. Biol. 22, , 15-25.[Abstract/Free Full Text]

Das, M., Bouchey, D. M., Moore, M. J., Hopkins, D. C., Nemenoff, R. A., and Stenmark, K. R. ((2001). ). Hypoxia-induced proliferative response of vascular adventitial fibroblasts is dependent on G-protein-mediated activation of mitogen-activated protein kinases. J. Biol. Chem. 276, , 15631-15640.[Abstract/Free Full Text]

Das, M., Dempsey, E. C., Reeves, J. T., and Stenmark, K. R. ((2002). ). Selective expansion of fibroblast subpopulations from pulmonary artery adventitia in response to hypoxia. Am. J. Physiol. Lung Cell Mol. Physiol. 282, , L976-L986.[Abstract/Free Full Text]

Datta, K., Li, J., Bhattacharya, R., Gasparian, N., Wang, E., and Mukhopadhyay, D. ((2004). ). Protein kinase C zeta transactivates hypoxia-inducible factor alpha by promoting its association with p300 in renal cancer. Cancer Res. 64, , 456-462.[Abstract/Free Full Text]

Fields, A. P., Pincus, S. M., Kraft, A. S., and May, W. S. ((1989). ). Interleukin-3 and bryostatin 1 mediate rapid nuclear envelope protein phosphorylation in growth factor-dependent FDC-P1 hematopoietic cells. A possible role for nuclear protein kinase C. J. Biol. Chem. 264, , 21896-21901.[Abstract/Free Full Text]

Hirai, T., and Chida, K. ((2003). ). Protein kinase C zeta (PKCzeta): activation mechanisms and cellular functions. J. Biochem. (Tokyo) 133, , 1-7.[Abstract/Free Full Text]

Hug, H., and Sarre, T. F. ((1993). ). Protein kinase C isoenzymes: divergence in signal transduction? Biochem. J. 291, , 329-343.

Hussain, S., Assender, J. A., Bond, M., Wong, L. F., Murphy, D., and Newby, A. C. ((2002). ). Activation of protein kinase C zeta is essential for cytokine-induced metalloproteinase-1, -3, and -9 secretion from rabbit smooth muscle cells and inhibits proliferation. J. Biol. Chem. 277, , 27345-27352.[Abstract/Free Full Text]

Kim, S. J., Chang, Y. Y., Kang, S. S., and Chun, J. S. ((1997). ). Phorbol ester effects in atypical protein kinase C zeta overexpressing NIH3T3 cells: possible evidence for crosstalk between protein kinase C isoforms. Biochem. Biophys. Res. Commun. 237, , 336-339.[CrossRef][Medline]

Kent, K. C., Mii, S., Harrington, E. O., Chang, J. D., Mallette, S., and Ware, J. A. ((1995). ). Requirement for protein kinase C activation in basic fibroblast growth factor-induced human endothelial cell proliferation. Circ. Res. 77, , 231-238.[Abstract/Free Full Text]

Keyse, S. M., and Emslie, E. A. ((1992). ). Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature 359, , 644-647.[CrossRef][Medline]

Keyse, S. M. ((1995). ). An emerging family of dual specificity MAP kinase phosphatases. Biochim. Biophys. Acta 1265, , 152-160.[Medline]

Lacasa, D., Agli, B., and Giudicelli, Y. ((1995). ). Zeta protein kinase C in rat preadipocytes: modulation by insulin and serum mitogenic factors and possible role in adipogenesis. Biochem. Biophys. Res. Comm. 217, , 123-130.[CrossRef][Medline]

Laderoute, K. R., Mendonca, H. L., Calaoagan, J. M., Knapp, A. M., Giaccia, A. J., and Strok, P. J. ((1999). ). Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity. 1999. J. Biol. Chem. 274, , 12890-12897.[Abstract/Free Full Text]

Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., and Parker, P. J. ((1998). ). Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281, , 2042-2045.[Abstract/Free Full Text]

Liu. C., Shi, Y., Ha, Z., Pan, Y., Liu, N., Han, S., Chen, Y., Lan, M., Qiao, T., and Fan, D. ((2003). ). Suppression of the dual-specificity phosphatase MKP-1 enhances HIF-1 trans-activation and increases expression of EPO. Biochem. Biophys. Res. Commun. 312, , 780-786.[CrossRef][Medline]

Lornejad-Schafer, M. R., Schafer, C., Graf, D., Haussinger, D., and Schliess, F. ((2003). ). Osmotic regulation of insulin-induced mitogen-activated protein kinase phosphatase (MKP-1) expression in H4IIE rat hepatoma cells. Biochem. J. 371, , 609-619.[CrossRef][Medline]

Mas, V. M., Hernandez, H., Plo, I., Bezombes, C., Maestre, N., Quillet-Mary, A., Filomenko, R., Demur, C., Jaffrezou, J. P., and Laurent, G. ((2003). ). Protein kinase C zeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin. Blood 101, , 1543-1550.[Abstract/Free Full Text]

Neri, L. M., Billi, A. M., Manzoli, L., Rubbini, S., Gilmour, R. S., Cocco, L., and Martelli, A. M. ((1994). ). Selective nuclear translocation of protein kinase C alpha in Swiss 3T3 cells treated with IGF-I, PDGF and EGF. FEBS Lett. 347, , 63-68.[CrossRef][Medline]

Nishida, E., and Gotoh, Y. ((1993). ). The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem. Sci. 18, , 128-131.[CrossRef][Medline]

Nishizuka, Y. ((1992). ). Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258, , 607-614.[Abstract/Free Full Text]

Noguchi, T., Metz, R., Chen, L., Mattei, M. G., Carrasco, D., and Bravo, R. ((1993). ). Structure, mapping, and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth. Mol. Cell. Biol. 13, , 5195-5205.[Abstract/Free Full Text]

Pal, S., Datta, K., Khosravi-Far, R., and Mukhopadhyay, D. ((2001). ). Role of protein kinase C zeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J. Biol. Chem. 276, , 2395-2403.[Abstract/Free Full Text]

Plows, D., Briassouli, P., Owen, C., Zoumpourlis, V., Garrett, M. D., and Pintzas, A. ((2002). ). Ecdysone-inducible expression of oncogenic Ha-Ras in NIH 3T3 cells leads to transient nuclear localization of activated extracellular signal-regulated kinase regulated by mitogen-activated protein kinase phosphatase-1. Biochem. J. 362, , 305-315.[CrossRef][Medline]

Pouyssegur, J., Volmat, V., and Lenormand, P. ((2002). ). Fidelity and spatiotemporal control in MAP kinase (ERKs) signalling. Biochem. Pharmacol. 64, , 755-763.[CrossRef][Medline]

Powell, D. J., Turban, S., Gray, A., Hajduch, E., and Hundal, H. S. ((2004). ). Intracellular ceramide synthesis and protein kinase C zeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem. J. 382, , 619-629.[CrossRef][Medline]

Reffas, S., and Schlegel, W. ((2000). ). Compartment-specific regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) by ERK-dependent and non-ERK-dependent inductions of MAPK phosphatase (MKP)-3 and MKP-1 in differentiating P19 cells. Biochem. J. 352, , 701-708.

Rey, F. E., and Pagano, P. J. ((2002). ). The reactive adventitia: fibroblast oxidase in vascular function. Arterioscler. Thromb. Vasc. Biol. 22, , 1962-1971.[Abstract/Free Full Text]

Sartore, S., Chiavegato, A., Faggin, E., Franch, R., Puato, M., Ausoni, S., and Pauletto, P. ((2001). ). Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ. Res. 89, , 1111-1121.[Abstract/Free Full Text]

Seta, K. A., Kim, R., Kim, H. W., Millhorn, D. E., and Beitner-Johnson, D. ((2001). ). Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. J. Biol. Chem. 276, , 44405-44412.[Abstract/Free Full Text]

Slack, D. N., Seternes, O. M., Gabrielsen, M., and Keyse, S. M. ((2001). ). Distinct binding determinants for ERK2/p38alpha and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1. J. Biol. Chem. 276, , 16491-16500.[Abstract/Free Full Text]

Short, M., Nemenoff, R. A., Zawada, W. M., Stenmark, K. R., and Das, M. ((2004). ). Hypoxia induces differentiation of pulmonary artery adventitial fibroblasts into myofibroblasts. Am. J. Physiol. Cell Physiol. 286, , C416-C425.[Abstract/Free Full Text]

Sodhi, C. P., Batlle, D., and Sahai, A. ((2000). ). Osteopontin mediates hypoxia-induced proliferation of cultured mesangial cells: Role of protein kinase C and MAPK. Kidney Int. 58, , 691-700.[CrossRef][Medline]

Stawowy, P., Goetze, S., Margeta, C., Fleck, E., and Graf, K. ((2003). ). LPS regulate ERK1/2-dependent signaling in cardiac fibroblasts via protein kinase C-mediated MKP-1 induction. Biochem. Biophys. Res. Commun. 303, , 74-80.[CrossRef][Medline]

Stenmark, K. R., Fasules, J., Voelkel, N. F., Henson, J., Tucker, A., Wilson, H., and Reeves, J. T. ((1987). ). Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4300 m. J. Appl. Physiol. 62, , 821-830.[Abstract/Free Full Text]

Stenmark, K. R., and Mecham, R. P. ((1997). ). Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu. Rev. Physiol. 59, , 89-144.[CrossRef][Medline]

Stenmark, K. R., Bouchey, D., Nemenoff, R., Dempsey, E. C., and Das, M. ((2000). ). Hypoxia-induced pulmonary vascular remodeling: contribution of the adventitial fibroblasts. Physiol. Res. 49, , 503-517.[Medline]

Theodore, L., Derossi, D., Chassaing, G., Llirbat, B., Kubes, M., Jordan, P., Chneiweiss, H., Godement, P., and Prochiantz, A. ((1995). ). Intraneuronal delivery of protein kinase C pseudosubstrate leads to growth cone collapse. J. Neurosci. 15, , 7158-7167.[Abstract]

Toker, A. ((1998). ). Signaling through protein kinase C. Front, Biosci. 3, , D1134-D1147.[Medline]

Tuteja, R., and Tuteja, N. ((1998). ). Nucleolin: a multifunctional major nucleolar phosphoprotein. Crit. Rev. Biochem. Mol. Biol. 33, , 407-436.[CrossRef][Medline]

Valledor, A. F., Xaus, J., Comalada, M., Soler, C., and Celada, A. ((2000). ). Protein kinase C epsilon is required for the induction of mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J. Immunol. 164, , 29-37.[Abstract/Free Full Text]

Xaus, J., Comalada, M., Valledor, A. F., Cardo, M., Herrero, C., Soler, C., Lloberas, J., and Celada, A. ((2001). ). Molecular mechanisms involved in macrophage survival, proliferation, activation or apoptosis. Immunobiology 204, , 543-550.[CrossRef][Medline]

Yano, K., Bauchat, J. R., Liimatta, M. B., Clemmons, D. R., and Duan, C. ((1999). ). Down-regulation of protein kinase C inhibits insulin-like growth factor I-induced vascular smooth muscle cell proliferation, migration, and gene expression. Endocrinology 140, , 4622-4632.[Abstract/Free Full Text]

Zhang, B., Hosaka, M., Sawada, Y., Torii, S., Mizutani, S., Ogata, M., Izumi, T., and Takeuchi, T. ((2003). ). Parathyroid hormone-related protein induces insulin expression through activation of MAP kinase-specific phosphatase-1 that dephosphorylates c-Jun NH2-terminal kinase in pancreatic beta-cells. Diabetes 5, , 2720-2730.

Zhong, H., Belardinelli, L., Maa, T., and Zeng, D. ((2005). ). Synergy between A2B Adenosine receptors and hypoxia in activating human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 32, , 2-8.[Abstract/Free Full Text]

This article has been cited by other articles:

				S. Torii, N. Okamura, Y. Suzuki, T. Ishizawa, K.-i. Yasumoto, and K. Sogawa Cyclic AMP Represses the Hypoxic Induction of Hypoxia-inducible Factors in PC12 Cells J. Biochem., December 1, 2009; 146(6): 839 - 844. [Abstract] [Full Text] [PDF]

				S. L. Lomonaco, S. Kahana, M. Blass, Y. Brody, H. Okhrimenko, C. Xiang, S. Finniss, P. M. Blumberg, H.-K. Lee, and C. Brodie Phosphorylation of Protein Kinase C{delta} on Distinct Tyrosine Residues Induces Sustained Activation of Erk1/2 via Down-regulation of MKP-1: ROLE IN THE APOPTOTIC EFFECT OF ETOPOSIDE J. Biol. Chem., June 20, 2008; 283(25): 17731 - 17739. [Abstract] [Full Text] [PDF]

				M. Das, N. Burns, S. J. Wilson, W. M. Zawada, and K. R. Stenmark Hypoxia exposure induces the emergence of fibroblasts lacking replication repressor signals of PKC{zeta} in the pulmonary artery adventitia Cardiovasc Res, June 1, 2008; 78(3): 440 - 448. [Abstract] [Full Text] [PDF]

				K. E Corcoran, A. Malhotra, C. A Molina, and P. Rameshwar Stromal-derived factor-1{alpha} induces a non-canonical pathway to activate the endocrine-linked Tac1 gene in non-tumorigenic breast cells J. Mol. Endocrinol., March 1, 2008; 40(3): 113 - 123. [Abstract] [Full Text] [PDF]

				C. M. Kinney, U. M. Chandrasekharan, L. Mavrakis, and P. E. DiCorleto VEGF and thrombin induce MKP-1 through distinct signaling pathways: role for MKP-1 in endothelial cell migration Am J Physiol Cell Physiol, January 1, 2008; 294(1): C241 - C250. [Abstract] [Full Text] [PDF]

				K. R. Stenmark, K. A. Fagan, and M. G. Frid Hypoxia-Induced Pulmonary Vascular Remodeling: Cellular and Molecular Mechanisms Circ. Res., September 29, 2006; 99(7): 675 - 691. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: E05-09-0869v1 17/4/1995    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Short, M. D. Articles by Das, M. Search for Related Content PubMed PubMed Citation Articles by Short, M. D. Articles by Das, M.